Lewis, D. J., Jerkeman, M., Wright, D., Glimelius, I., Poulsen, C. B., Pasanen, A., Rawstron, A., Wader, K., Morley, N., Burton, C., Lagerlöf, I., Dalal, S., De Tute, R., McNamara, C., Crosbie, N.
, Toldbod, H. E., Sanders, J., Allgar, V., Aroori, S. ... ENRICH investigators (2025).
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.
The Lancet,
406(10514), 1953-1968.
https://doi.org/10.1016/S0140-6736(25)01432-1Reinhardt, J., Dankbar, B., Geers, F., Werbenko, E., Geyer, C., Bleckmann, A., Menck, K., Grözinger, A., Hartmann, W., Tio, J., Höltke, C., Helfen, A.
, Lodberg, A., Al-Qasemi, R., Beckmann, D., Bödecker, S., Kleimann, S., Wessendorf, L., Wawersig, D. ... Wehmeyer, C. (2025).
Pharmacological inhibition of myostatin effectively ameliorates osteolytic lesions in syngeneic and xenograft breast cancer mouse models.
Oncogene,
44(49), 4781–4795.
https://doi.org/10.1038/s41388-025-03622-7